Saturday 17 October 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 40.0% and free cash flow grew 64.7%, each against the same quarter a year earlier.
142.78
9.84
−6.45%
Follow BLTE
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 8.80 | 11.00 | 31.01 | 49.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 44.70 | 46.70 | 86.53 | 169.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 12 | 16 | 20 | 25 | 23 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | (6) | (10) | (13) | (32) | (36) | (78) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | (6) | (10) | (13) | (32) | (36) | (78) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.65) | (1.01) | (0.65) | (1.19) | (1.18) | (2.31) | |||||
| Cash flow | — | — | — | — | (0.51) | (0.78) | (0.57) | (1.12) | (0.96) | (1.10) | |||||
| Capex | — | — | — | — | 0.00 | (0.01) | (0.02) | 0.00 | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | (0.51) | (0.79) | (0.59) | (1.12) | (0.96) | (1.11) | |||||
| Book value | — | — | — | — | (0.80) | (1.58) | 2.08 | 3.40 | 4.78 | 22.97 | |||||
| Shares, m | — | — | — | — | 9 | 10 | 20 | 27 | 31 | 34 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (4) | (7) | (11) | (30) | (29) | (37) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (4) | (8) | (12) | (30) | (29) | (37) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 25 | 16 | 41 | 86 | 141 | 484 | ||||
| Total debt | — | — | — | — | 32 | 32 | 1 | — | — | — | |||||
| Net debt | — | — | — | — | (26) | (17) | (42) | (88) | (145) | (492) | |||||
| Shareholders’ equity | — | — | — | — | (7) | (15) | 42 | 90 | 146 | 770 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (43.85) | (40.40) | (45.54) | (29.29) | (16.64) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (870.38) | (3,719.87) | (18.93) | |||||
| ROE | — | — | — | — | 0.00 | 87.36 | (95.79) | (47.95) | (30.60) | (16.94) | |||||
Negative figures in brackets.
Charts ten years each
Belite Bio, Inc. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | $6.9B | — (loss-making) | — (loss-making) | +1,349.13% (above 0%: growing) | n/m | −43.54% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IOVA Iovance Biotherapeutics, Inc. | $6.7B | — (loss-making) | — (loss-making) | +65.65% (above 0%: growing) | n/m | +11.52% (above 0%: growing) | 56.10% | (52.26%) | Compare |
| BLTE Belite Bio, Inc. Sponsored ADR | $6.2B | — (loss-making) | — | — | n/m | +64.67% (above 0%: growing) | — | 0.00% | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.1B | — (loss-making) | — (loss-making) | +46.91% (above 0%: growing) | n/m | +60.74% (above 0%: growing) | 87.47% | (68.14%) | Compare |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 29.5× | 54.7× | +33.73% (above 0%: growing) | +868.00% (above 0%: growing) | +35.53% (above 0%: growing) | 94.95% | 13.49% | Compare |
| IMVT Immunovant, Inc. | $5.7B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KOD Kodiak Sciences Inc. | $5.5B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGON CG Oncology, Inc. | $5.5B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| MIRM Mirum Pharmaceuticals, Inc. | $5.4B | — (loss-making) | — (loss-making) | +37.92% (above 0%: growing) | n/m | −681.46% (below 0%: shrinking) | 82.78% | (24.14%) | Compare |
| Median of peers | $5.8B | — | — | +56.28% | — | −19.91% | 69.44% | (12.07%) |
Belite Bio, Inc. Sponsored ADR (BLTE) key facts
- Concern: Belite Bio, Inc. Sponsored ADR reported a net loss of $77.6 million, or a loss of $2.31 per share, for fiscal 2025.
- Belite Bio, Inc. Sponsored ADR (BLTE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BLTE traded at $142.78, a market capitalization of $6.2 billion.
- Return on equity was −16.9% and debt-to-equity 0.00.